| Lizenz: Creative Commons Namensnennung 4.0 International PDF - Veröffentlichte Version (3MB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-415751
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.41575
Zusammenfassung
Therapy of acute myeloid leukemia (AML) is unsatisfactory. Histone deacetylase inhibitors (HDACi) are active against leukemic cells in vitro and in vivo. Clinical data suggest further testing of such epigenetic drugs and to identify mechanisms and markers for their efficacy. Primary and permanent AML cells were screened for viability, replication stress/DNA damage, and regrowth capacities after ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags
Downloadstatistik